SCHEMBL6962472

SCHEMBL6962472

Cc1ccc2c(c1)C(=CCCBr)c1ccccc1CC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.54
CYP1A2 P05177 4/20 0.54
RET P07949 3/20 0.54
CYP2C19 P33261 2/20 0.54
SLC6A2 P23975 5/20 0.52
HRH1 P35367 5/20 0.52
LMNA P02545 4/20 0.52
HTR2B P41595 4/20 0.52
KCNH2 Q12809 4/20 0.52
CHRM2 P08172 3/20 0.52
CHRM4 P08173 3/20 0.52
HTR1A P08908 3/20 0.52
CHRM5 P08912 3/20 0.52
ADRA2A P08913 3/20 0.52
CYP2D6 P10635 3/20 0.52
CHRM1 P11229 3/20 0.52
DRD2 P14416 3/20 0.52
ADRA2B P18089 3/20 0.52
ADRA2C P18825 3/20 0.52
CHRM3 P20309 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16938066 0.91 CYP3A4 (0.54) CYP3A4CYP1A2RETCYP2C19SLC6A2
SCHEMBL653565 0.86 CYP3A4 (0.63) CYP3A4CYP1A2RETCYP2C19SLC6A2
SCHEMBL11202872 0.83 CYP3A4 (0.50) CYP3A4CYP1A2RETCYP2C19SLC6A2
SCHEMBL11202871 0.83 CYP3A4 (0.50) CYP3A4CYP1A2RETCYP2C19SLC6A2
SCHEMBL15908322 0.76 CYP3A4 (0.50) CYP3A4CYP1A2RETCYP2C19SLC6A2
SCHEMBL16938071 0.75 HTR2B (0.78) CYP3A4CYP1A2RETCYP2C19SLC6A2
SCHEMBL22147029 0.75 LMNA (0.78) CYP3A4CYP1A2RETCYP2C19SLC6A2
SCHEMBL21859431 0.75 LMNA (0.78) CYP3A4CYP1A2RETCYP2C19SLC6A2
SCHEMBL16938075 0.75 HTR2B (0.78) CYP3A4CYP1A2RETCYP2C19SLC6A2
SCHEMBL12362400 0.75 SLC6A2 (0.49) CYP3A4CYP1A2RETCYP2C19SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6613791-B1 Treating migraine, neurogenic inflammation, rheumatoid arthritis or insulin resistance NOVO NORDISK A/S (DK) 2003-09-02 US disclosed
EP-0820451-B1 NOVEL HETEROCYCLIC COMPOUNDS NOVO NORDISK AS (DK) 2003-01-15 EP disclosed
US-6239148-B1 TREATMENT OF PAINFUL, HYPERALGESIC AND/OR INFLAMMATORY CONDITIONS IN WHICH C-FIBERS PLAY A ROLE BY ELICITING NEUROGENIC PAIN, INSULIN RESISTANCE IN DIABETES MELLITUS OR AGING, INHIBIT INSULIN ANTAGONIZING PEPTIDE, NOVO NORDISK A/S (DK) 2001-05-29 US disclosed
US-6166009-A N-substituted azaheterocyclic carboxylic acids and esters thereof NOVO NORDISK A/S (DK) 2000-12-26 US disclosed
US-6110913-A ANTIINFLAMMATORY AGENTS, ANALGESICS NOVO NORDISK A/S (DK) 2000-08-29 US disclosed
US-6071901-A TREATING PAIN, HYPERALGESIA AND/OR INFLAMMATORY CONDITIONS IN WHICH C-FIBERS PLAY A PATHOPHYSIOLOGICAL ROLE; INHIBITION OF NEUROGENIC INFLAMMATION INVOLVING THE RELEASE OF NEURO-PEPTIDE FROM PERIPHERAL AND CENTRAL ENDINGS OF SENSORY NERVES NOVO NORDISK A/S (DK) 2000-06-06 US disclosed
EP-0820451-A1 NOVEL HETEROCYCLIC COMPOUNDS NOVO NORDISK A/S (DK) 1998-01-28 EP disclosed
WO-1996031498-A1 NOVEL HETEROCYCLIC COMPOUNDS NOVO NORDISK A/S (DK) 1996-10-10 WO disclosed